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学 位 論 文 要 約  
 
 博士論文題目 S100A11 promotes tumorigenesis of non-small cell lung cancer through 
cytoskeleton integrity maintenance and YAP activation (S100A11 は F-ア
クチン細胞骨格の恒常性維持と YAP 活性化によって非小細胞 肺がんの発が
ん性を促進する) 
Background: Advancements in medical technology and the accompanying growth in our knowledge of 
cancer biology has led to remarkable progress against cancer. Nevertheless; despite such significant 
achievement, cancer still takes many lives. Non-small cell lung cancer (NSCLC), for example, is a 
leading cause of death from cancer. Despite the development of EGFR kinase inhibitors, the disease 
burden is still significant and new targets are in high demand. For my thesis work I focused on members 
of the S100 family which show aberrant expression in various human cancers. S100 proteins are 
Ca2+-binding proteins and some members have shown therapeutic application. Many members of the 
family are dysregulated in cancer and facilitate disease progression; however, the underlying mechanisms 
remain incompletely understood.  
Methods and Results: I found S100A11 to be overexpressed in NSCLC cells and through loss of 
function approach identified its importance for the tumorigenesis of NSCLC. S100A11 knockdown or 
knockout abrogated the proliferation, tumorigenicity, migration and invasion of H1975 cells. Moreover, I 
discovered that silencing of S100A11 impaired F-actin organization, disrupted focal adhesion, and 
delayed cell spreading. Accordingly, I examined regulatory pathways behind its implication and found it 
to be important for the activation of the Yes associated protein (YAP) oncogene whose regulation is 
dependent on the actin cytoskeleton and cellular mechanical tension. Supportively, I found that S100A11- 
depletion conferred decreased nuclear localization of YAP and induced increased YAP phosphorylation 
suggesting that S100A11 depletion inactivates YAP. Further, I found that loss of S100A11 decreased YAP 
activity and thereby the expression of its downstream target genes (CTGF, CYR61, and ANKRD1). 
Finally, I validated the importance of S100A11 and YAP to the biology of H1975 cells by reintroducing 
S100A11 to S100A11 knockout cells and suppressing YAP activity from wild type H1975 cells using a 




restored aggressive properties of H1975 cells while suppression of YAP activity resulted in complete 
abolition of tumor growth in vivo. These results underscore the importance of YAP to the biology of 
H1975 cells and explain why S100A11- actin mediated suppression of its activity attenuated the 
biological functions of these aggressive lung adenocarcinoma cells.  
Conclusion and prospects: In this study, I report a novel pathway whereby S100A11 drives the 
tumorigenesis of NSCLC cells through sustenance of F-actin integrity and regulation of YAP activity. 
YAP is a well-known oncogene, and both YAP and S100A11 have been reported to be of therapeutic 
significance in NSCLC. It is of relevance to investigate how combined targeting of S100A11 and YAP 
may be exploited to further explore the therapeutic potential of these molecules in NSCLC with emphasis 
on achieving clinical value. 
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